elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
批准号:
8842956
负责人:
Davide Ruggero
金额:
$38.14万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-05-01 至 2019-04-30
关键词:
5&apos Untranslated RegionsBortezomibCell SurvivalCell physiologyCellsCellular StressCellular Stress ResponseCessation of lifeDNA DamageDataDependencyDevelopmentEmployee StrikesFoundationsGene ExpressionGeneticGenetic TranslationMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMass Spectrum AnalysisMediatingMessenger RNAMetabolicMolecularNon-Small-Cell Lung CarcinomaNormal CellNucleotidesOncogenicOxidative StressPathway interactionsPhenotypePopulationProcessProteinsRNA Cap-Binding ProteinsRNA-Binding ProteinsReactive Oxygen SpeciesRegimenRegulatory ElementRoleStressTherapeuticTherapeutic AgentsTranscriptTranslationsUntranslated RegionsUp-Regulationarmbasebiological adaptation to stresscancer cellcancer stem cellcell transformationdesigndosagegenome-widein vivoloss of functionmetaplastic cell transformationmouse modelneoplastic cellnovelnovel therapeuticsprogramspublic health relevanceresearch studyresponsesmall moleculestress tolerancetumortumor growthtumor progressiontumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A fundamental, hard-wired response to oncogenic transformation is enhanced cellular stress (for example, oxidative, replicative, metabolic, ER stress, and DNA damage) that is a hallmark of cancer cells. These common stress phenotypes must be tolerated by cancer cells through stress support pathways. Moreover, adaptation to stress is required for cancer cell survival, and consequently cancer cells may become dependent on stress response pathways that do not ordinarily perform such a vital function in normal cells. Thus, targeting these associated vulnerabilities to stress adaptation are clearly paramount and offer a tremendous window of opportunity for a synthetic lethal interaction that may elicit selective death of cancer cells. Despite the tremendous importance of the stress phenotype of cancer cells, there is a large gap in our understanding of the genetic basis for how stress tolerance is maintained in transformed cells, thereby limiting our ability to design rationa therapeutic agents. Cells require adaptation responses in gene expression to respond to cellular stress. Strikingly, our findings reveal that the major cap binding protein eIF4E is unexpectedly a central integrator of the translation program for the adaption of cancer cells to oncogenic stress.
By generating the first genetic loss-of-function mouse model for eIF4E, we have unexpectedly discovered that 50% reductions in eIF4E have no effect on normal development or cellular function but instead are specifically limiting for oncogenic transformation. Utilizing unbiased genome-wide translational profiling, we find that eIF4E is selectively limiting for the translationof specific subsets of mRNAs involved in cellular stress response pathways, including oxidative stress (e.g. Fth1, Gclc,) and ER stress (e.g. Atf6, XBP-1), at least in part, through a novel cis-acting regulatory sequence in their 5'UTRs that sensitizes these mRNAs to eIF4E dosage. Moreover, our preliminary data demonstrate that eIF4E-dependent control of these stress response pathways is critical for tumor cell survival and oncogenic transformation. These findings lay the foundation for this proposal, which seeks to open a new portal into our understanding of the translation program that maintains the adaptation of cancer cells to stress and develops a novel therapeutic regimen to target this vulnerability of transformed cells. In Aim 1, we will assess the role of eIF4E dependent control of oxidative stress in non-small cell lung carcinoma in vivo. In Aim 2, we will define the molecular mechanism by which eIF4E directs the stress-induced oncogenic translation program through a novel cis-acting regulatory element. In Aim 3, we will determine the contribution of eIF4E to cellular transformation through translational
control of the unfolded protein response (UPR).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ERa is a novel RNA-binding protein controlling breast cancer
-
批准号:10580061
-
项目类别:
-
资助金额:$46.88万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
ERa is a novel RNA-binding protein controlling breast cancer
-
批准号:10460857
-
项目类别:
-
资助金额:$47.84万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
-
批准号:10522626
-
项目类别:
-
资助金额:$66.62万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Remodeling the translatome in N-myc mediated medulloblastoma and its therapeutic implications
-
批准号:10672311
-
项目类别:
-
资助金额:$66.62万
-
财政年份:2022
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10664866
-
项目类别:
-
资助金额:$94.96万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10226938
-
项目类别:
-
资助金额:$96.9万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
Mechanisms of regulated translation control in cancer and its therapeutic implications
-
批准号:10436946
-
项目类别:
-
资助金额:$94.96万
-
财政年份:2019
-
负责人:Davide Ruggero
-
依托单位:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
-
批准号:9265424
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
elF4E-Dependent Translation Control in the Oncogenic Stress Response and Cancer
-
批准号:8674344
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
MYCN, mTOR and translation control in medulloblastoma
-
批准号:9304355
-
项目类别:
-
资助金额:$60.35万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
Diversity Supplement for MYCN, mTOR and translation control in medulloblastoma
-
批准号:9067800
-
项目类别:
-
资助金额:$1.82万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
MYCN, mTOR and translation control in medulloblastoma
-
批准号:8801526
-
项目类别:
-
资助金额:$63.22万
-
财政年份:2014
-
负责人:Davide Ruggero
-
依托单位:
Deciphering the role of the translational oncogenic program in Prostate Cancer
-
批准号:9403874
-
项目类别:
-
资助金额:$41.91万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
RIBOSOMAL RNA SEQUENCE ANALYSIS
-
批准号:8363850
-
项目类别:
-
资助金额:$1.19万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8515756
-
项目类别:
-
资助金额:$40.97万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8187270
-
项目类别:
-
资助金额:$38.64万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8919267
-
项目类别:
-
资助金额:$35.31万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8703036
-
项目类别:
-
资助金额:$34.41万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
Pharmcogenomic dissection of mTOR translational targets in prostate cancer
-
批准号:8323911
-
项目类别:
-
资助金额:$43.04万
-
财政年份:2011
-
负责人:Davide Ruggero
-
依托单位:
The role of deregulated protein synthesis control in Myc-induced tumorigenesis
-
批准号:7695534
-
项目类别:
-
资助金额:$31.3万
-
财政年份:2009
-
负责人:Davide Ruggero
-
依托单位:
海外基金